Cargando…
Side Effects Following Administration of the First Dose of Oxford-AstraZeneca’s Covishield Vaccine in Bangladesh: A Cross-Sectional Study
In response to the raging COVID-19 pandemic, Bangladesh started its vaccine administration in early 2021; however, due to the rapid development and launch of the vaccines in the market, many people had concerns regarding the safety of these vaccines. The purpose of this study was to evaluate the sid...
Autores principales: | Jahan, Nishat, Rahman, Fahad Imtiaz, Saha, Poushali, Ether, Sadia Afruz, Roknuzzaman, ASM, Sarker, Rapty, Kalam, Khondoker Tashya, Haq, Kashfa, Nyeen, Julkar, Himi, Humayra Zaman, Hossain, Md. Nazmul, Chowdhury, Mahtab Hossain, Uddin, Mostafa Moin, Alam, Nur Haque |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544399/ https://www.ncbi.nlm.nih.gov/pubmed/34698203 http://dx.doi.org/10.3390/idr13040080 |
Ejemplares similares
-
Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
Publicado: (2021) -
AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Publicado: (2021) -
Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Publicado: (2021) -
Vaccin Oxford/AstraZeneca, mode d’emploi
por: Dalmat, Yann-Mickael
Publicado: (2021) -
Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021)